# PDS Biotechnology Corporation (PDSB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PDSB
## Company Profile
- Ticker: PDSB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cancer Peptide Vaccines, Immunotherapy, Oncology
## Stock Data
- Close: 0.242 USD
- Market cap: 64746157.48 USD
- Last updated: 2026-08-12
## Business Overview
### Targeted Cancer Immunotherapy
PDS Biotechnology develops immunotherapies intended to activate antitumor immunity while directing immune stimulation toward the tumor microenvironment.
### PDS0301
PDS0301 is a tumor-targeted interleukin-12 immunocytokine designed to enhance local immune activity while limiting systemic IL-12 exposure. It is now the company's lead internal development program.
### Solid-Tumor Evidence
PDS0301 has been clinically evaluated in metastatic colorectal cancer, prostate cancer, and other solid tumors. Early data support further investigation in combinations intended to overcome treatment resistance.
### PDS0101 Strategy
PDS Biotechnology discontinued internal funding of the VERSATILE-003 Phase 3 program and is seeking partnership or externally funded pathways for continued development of PDS0101.
## Why The Stock Is Moving

The latest monitored company update is “PDS Biotech Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Recent News
- 2026-08-13 12:30 EST — [PDS Biotech Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PDSB/pds-biotech-reports-second-quarter-2026-financial-results-a0124437) — Source: PDS Biotechnology Corporation
- 2026-08-11 12:25 EST — [PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101](https://biopharmsignal.com/news/PDSB/pds-biotech-announces-strategic-refocus-prioritizing-pds0301-in-metastatic-color-b990cc7f) — Source: PDS Biotechnology Corporation
- 2026-05-13 11:00 EST — [PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update](https://biopharmsignal.com/news/PDSB/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-p-0e7c9dd2) — Source: PDS Biotechnology Corporation
- 2026-05-06 12:00 EST — [PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results](https://biopharmsignal.com/news/PDSB/pds-biotech-announces-conference-call-and-webcast-for-2026-first-quarter-financi-02129dba) — Source: PDS Biotechnology Corporation
- 2026-04-15 12:45 EST — [PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial](https://biopharmsignal.com/news/PDSB/pds-biotech-announces-publication-of-positive-pds01adc-interim-phase-2-clinical--180f6097) — Source: PDS Biotechnology Corporation